Zoledronic acid inhibits the growth of leukemic MLL-AF9 transformed hematopoietic cells. Issue 6 (June 2020) - Chiarella, Emanuela
Abstract: A leukemic in vitro model produced by transducing Cord Blood derived-hematopoietic CD34 + cells with the MLL-AF9 translocation resulting in the oncogenic fusion protein, is used to assess for sensitivity to Zoledronic acid. These cells are practically immortalized and are of myeloid origin. Proliferation, clonogenic and stromal co-culture assays showed that the MLL-AF9 cells were considerably more sensitive to Zoledronic acid than normal hematopoietic CD34 + cells or MS-5 stromal cells. The MLL-AF9 cells were notably more inhibited by Zoledronic acid when cultured as colonies in 3 dimensions, requiring cell-cell contacts compared to suspension expansion cultures. This is coherent with the mechanism of action of Zoledronic acid inhibiting farnesyl diphosphate synthase which results in a block in prenylation of GTPases such that their role in the membrane is compromised for cell-cell contacts. Zoledronic acid can be proposed to target the MLL-AF9 leukemic stem cells before they emerge from the hematopoietic niche, which being in proximity to bone osteoclasts where Zoledronic acid is sequestered can be predicted to result in sufficient levels to result in an anti-leukemic action. Abstract : Biological sciences; Cell biology; Biochemistry; Molecular biology; Cancer research; Acute myeloid leukemia, MLL-AF9 gene rearrangement, Bisphosphonate, Zoledronic acid